drugset / Trial / NCT00554658

Quetiapine Induced Neuroplasticity in First-episode Schizophrenic Patients

NCT00554658

Phase 4 Completed 30 enrolled University of Regensburg AstraZeneca · collab
NaSingle-groupOpen-label

Summary

Aim of the study is to assess the effect of quetiapine treatment in neuroleptic naive, first-episode schizophrenic patients on aspects of functional and structural neuroplasticity assessed by means of transcranial magnetic stimulation and voxel-based morphometry. Main outcome measure is a change in gray matter density under quetiapine treatment from baseline to steady-state-treatment after 3 weeks.

Timeline

Start
2008-03
Primary completion
2010-12
Completion
2011-03

Drugs

EvaluationDrugModalityDoseRoute
Comparator Quetiapine Small molecule 400 mg
Comparator Quetiapine Small molecule 800 mg

Indications